GlyMCA, which cannot undergo enterohepatic circulation to reach the gallbladder,[7, 8] prevents CGD by inhibiting WD‐induced intestinal FXR‐ceramide signaling,[8] reducing systemic metabolic stress and alleviating bile CSI. Here, NR1H4 is linked to chronic granulomatous disease.